Pfizer in investment phase in India as it moves into diabetes and branded generics
This article was originally published in Scrip
Pfizer India, traditionally known for its dependence on the parent company's innovative product portfolio, is expanding its horizons on the domestic market to propel growth. The Indian arm, which has just moved into the diabetes segment, anticipates strong growth in the branded generics segment, where it is also planning to take the plunge.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.